Gitlin J D, Soll R F, Parad R B, Horbar J D, Feldman H A, Lucey J F, Taeusch H W
Pediatrics. 1987 Jan;79(1):31-7.
We conducted a prospective, randomized, unblinded, controlled trial of exogenous bovine surfactant (surfactant TA) in premature infants requiring ventilator support for the treatment of severe hyaline membrane disease. Forty-one low birth weight infants with severe hyaline membrane disease were randomly assigned to saline or surfactant therapy and treated within eight hours of birth. Significant improvements in oxygenation (increased arterial/alveolar PO2) and respiratory support (decreased mean airway pressure) were seen in the group receiving surfactant within four hours after treatment. These improvements were maintained in the surfactant-treated infants, who also had fewer pneumothoraces and fewer number of days in environments of fractional inspiratory oxygen greater than 0.4 mm Hg. No problems were associated with administration of surfactant, and no acute side effects were detected. We conclude that exogenous surfactant, administered early in the course of severe hyaline membrane disease, is an effective therapy that can diminish the amount of respiratory support required during the first 48 hours of life.
我们对需要呼吸机支持以治疗严重透明膜病的早产儿进行了一项前瞻性、随机、非盲、对照试验，使用外源性牛肺表面活性剂（表面活性剂TA）。41例患有严重透明膜病的低出生体重婴儿被随机分配接受生理盐水或表面活性剂治疗，并在出生后8小时内进行治疗。治疗后4小时内接受表面活性剂治疗的组中，氧合（动脉/肺泡PO2增加）和呼吸支持（平均气道压力降低）有显著改善。这些改善在接受表面活性剂治疗的婴儿中得以维持，他们发生气胸的次数较少，且在吸入氧分数大于0.4 mmHg的环境中停留的天数也较少。表面活性剂的给药未出现问题，也未检测到急性副作用。我们得出结论，在严重透明膜病病程早期给予外源性表面活性剂是一种有效的治疗方法，可减少出生后48小时内所需的呼吸支持量。
